Stem Cell Infusions Safely Boost Physical Function in Frail Older Adults

Frailty syndrome — characterised by muscle weakness, exhaustion, slow gait, low activity, and unintentional weight loss — affects up to 27% of adults over 65 and dramatically increases risk of falls, hospitalisation, and death. Current management strategies (exercise, nutrition, social support) have limited efficacy in advanced cases, and no approved disease-modifying biological therapy exists. Umbilical cord-derived mesenchymal stem cells (UC-MSCs) represent a promising candidate because of their immunomodulatory, anti-inflammatory, and tissue-regenerative properties demonstrated in preclinical models.

This phase 2 randomised, open-label, assessor-blinded trial at Vinmec Times City International General Hospital in Hanoi, Vietnam enrolled 147 frail adults aged 60–85 meeting Modified Fried Criteria (≥3 of 5 criteria) and Canadian Frailty Scale scores of 3–6. After a 10-person phase 1 safety run-in confirmed no serious adverse events, 148 participants were randomised to two groups: the UC-MSC group (n=74) received two intravenous infusions of allogeneic UC-MSCs at 1.5×10⁶ cells/kg, spaced three months apart, plus oral supplements (vitamins, calcium, zinc, and joint support); the control group (n=74) received supplements alone. Follow-up visits occurred at baseline, 1, 3, 6, and 9 months.

The primary efficacy endpoint — SPPB total score at nine months — favoured the UC-MSC group by a least-squares mean difference of 1.1 points (95% CI: 0.6–1.6), exceeding the pre-specified minimal clinically important difference of 0.5 points. Secondary outcomes also showed improvements in the UC-MSC group: greater handgrip strength, more physical activity (CHAMPS questionnaire), reduced multidimensional fatigue (MFI), better knee function (WOMAC), and higher quality-of-life scores (SF-36 general health). Biomarker analyses revealed favourable shifts in inflammatory cytokines and reduced p16INK4a mRNA expression in CD3+ T cells — a marker of cellular senescence — suggesting a plausible biological mechanism underlying the functional gains.

On safety, 12 mild adverse events (headache, dizziness, chest discomfort) were reported in the UC-MSC group and resolved spontaneously without intervention. No serious adverse events or Grade ≥3 events attributable to UC-MSC therapy occurred across the entire trial. Pre-infusion anticoagulation (rivaroxaban) and antihistamine prophylaxis were used to mitigate infusion-related risks in this older, frail population.

The trial is the largest and longest randomised evaluation of UC-MSC therapy for frailty to date, and the first to combine comprehensive physical, patient-reported, and translational biomarker outcomes over nine months. Limitations include the open-label design, single-centre setting, and a predominantly Vietnamese patient population, which may limit generalisability. Nonetheless, the findings provide a strong rationale for phase 3 double-blind multicentre trials to confirm efficacy, optimise dosing, assess durability beyond nine months, and evaluate cost-effectiveness in broader, more comorbid older populations.